At Systasy Bioscience GmbH, we offer two positions to
highly motivated, driven, and skilled PhD students to conduct their research in the
area of cell-based assay development and their application in human disease models
to study the function of intrinsically disordered proteins (IDPs). Systasy has
state-of-the-art laboratories including next-generation sequencing technologies and
human stem cell culture. Our laboratories are located in central Munich.At Systasy
Bioscience GmbH, we offer two positions to highly motivated, driven, and skilled PhD
students to conduct their research in the area of cell-based assay development and
their application in human disease models to study the function of intrinsically
disordered proteins (IDPs). Systasy has state-of-the-art laboratories including
next-generation sequencing technologies and human stem cell culture. Our
laboratories are located in central Munich.
In project 1, the PhD candidate will establish an
array of cell-based assays for IDPs in human cell lines. Assays will use Systasy’s
splitSENSOR and EXTassay barcoding technologies to enable a multiplexed readout to
assess both the association to key interaction partners and the effect on
physiological signaling pathways. splitSENSOR and EXTassay barcoding technologies
are established at our site and were combined in a so-called targetProfiler approach
before (see Galinski
et al., 2018, Sci Reports as reference). Examples of IDPs to be
selected are, but not limited to, amyloid precursor protein (APP),
γ-secretase/presenilin, a-synuclein, Mint2, FKBP51, and calmodulin kinase II.
Furthermore, the candidate will profile interactions for selectivity and
specificity, and will assess IDP-directed antagonists in these assays.
In project 2, the PhD candidate will establish an
array of validated CRISPR mediated genetic perturbation tools to assess a gain- and
loss-of-function analysis of IDP interactions that are relevant to the regulation of
neuronal signaling and cell fate. To do this, the PhD candidate will e.g., apply
CRISPR inhibition (or knockout) directed on IDP candidates in a human disease model
and combine this technique with a multi-pathway profiling assay (using company-owned
barcoded pathwayProfiler assay, see Herholt et al., 2018, Sci Reports
as reference)
to identify affected targets and pathways (e.g., including cell fate, cell stress,
immune signaling, metabolism, pluripotency, neuronal signaling). Data obtained from
the pathway profiling will be complemented by (single cell) RNA-seq analyses.